Table 1.
Risk factors for haemorrhage in patients who bled
| 2003 | Cumulative results from previous years | Total | |
| Diagnosis of myeloproliferative disorder | 5 | 13 | 18 |
| Aspirin treatment | 3 | 7 | 10 |
| Warfarin treatment | 1* | 2† | 3 |
| Heparin treatment | 1 | 1 | |
| Disseminated intravascular coagulation | 2 | 2 | |
| Renal impairment | 2 | 2 | |
| Von Willebrand’s disease | 1 | 1 | |
| Other putative platelet dysfunction | 3 (2 AML, 1 MDS) | 4 (3 MDS, 1 AML) | 7 |
| Thrombocytopenia | 3 (platelet counts 6×109/l in ITP and 39 and 86×109/l in 2 patients with AML) | 7 (platelet counts 17×109/l in megaloblastic anaemia, 23×109/l in AML, 25 and 68×109/l in MDS, 38×109/l post-BMT, and 96×109/l in MPD) | 7 |
| Obesity | 1 | 3 | 4 |
*International normalised ratio (INR) between 3.5 and 9.9. †INRs 2.2 and 2.8.
AML, acute myeloid leukaemia; BMT, bone marrow transplantation; ITP, idiopathic (autoimmune) thrombocytopenic purpura; MDS, myelodysplastic syndrome; MPD myeloproliferative disorder.